IGF2 and cancer: Although additional studies using a larger number of cases are required, these findings suggest that the cixutumumab-induced increases in tumour-associated macrophages and fibroblasts may play a role in IGF-2 expression and predict resistance to IGF-1R monoclonal antibody-based therapies in cancer patients.